Different regulatory measures are in place to mitigate systemic risk for G-SIBs. Regulators often speak of two types of institutions that are “too big to fail”: systemically important ...
IL-23, or IL-17 reduced serious infections, while tofacitinib increased infection risk, according to one study.
CalSTRS established the risk-mitigating strategy portfolio in 2016 to reduce the impact of economic downturns by shifting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback